SPECT IMAGING OF DOPAMINE TRANSPORTER IN BRAIN DISORDERS
AbstractBACKGROUND Diagnosis of parkinsonism is based on medical history and clinical examination. Whenthe signs of parkinsonism are obvious (tremor at rest, rigidity, bradykinesia), the diagnosisis relatively easy. However, problems appear when clinical signs are not typical or distinctenough for making the proper diagnosis. Dopamine transporter imaging with radioactivetracer 123I-Ioflupane (DAT-SPECT) enables a clear evaluation of nigrostriatal degeneration and helps a clinician to make a correct diagnosis. This article discusses the role andindications of DAT-SPECT imaging in patients with movement disorders and in patientswith dementia. CONCLUSIONS DAT-SPECT enables clear differentiation of degenerative parkinsonisms from parkinsonisms and non-parkinsonian tremors in which the nigrostriatal pathway remains intact.DAT-SPECT also differentiates dementia with Lewy bodies from Alzheimer’s disease
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.